<DOC>
	<DOCNO>NCT02566304</DOCNO>
	<brief_summary>This clinical trial study use reduce intensity chemotherapy radiation therapy donor stem cell transplant treat patient hematologic malignancy . Giving low dos chemotherapy , cyclophosphamide fludarabine phosphate , donor stem cell transplant may help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Reducing intensity chemotherapy radiation may also reduce side effect donor stem cell transplant .</brief_summary>
	<brief_title>Reduced Intensity Chemotherapy Radiation Therapy Before Donor Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To demonstrate efficacy approach historical 2 step reduce intensity conditioning ( RIC ) approach `` vulnerable '' population define : patient hematopoietic cell transplant ( HCT ) -co-morbidity index ( CI ) /age score &gt; = 2 , score 5 base Sorror et al . data . SECONDARY OBJECTIVES : I . To compare non-relapse mortality ( NRM ) relapse relate mortality ( RRM ) rate 1 year patient treat study patient undergo haploidentical RIC hematopoietic stem cell transplantation ( HSCT ) report literature observe 2 step RIC trial . II . To determine incidence severity graft-versus-host disease ( GVHD ) patient undergo treated Thomas Jefferson University ( TJU ) RIC 2 step approach . III . To evaluate engraftment rate lymphoid reconstitution patient treat TJU RIC 2 step approach . OUTLINE : RIC : Patients receive fludarabine phosphate intravenously ( IV ) 60 minute day -10 -8 cyclophosphamide IV 2 hour day -3 -2 . Patients also undergo total body irradiation ( TBI ) follow donor lymphocyte infusion ( DLI ) day -6 . TRANSPLANT : Patients undergo cluster differentiation ( CD ) 34+ peripheral blood stem cell transplant day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus orally ( PO ) begin day -1 taper initiate day 42 mycophenolate mofetil IV twice daily ( BID ) day -1 28 absence GVHD . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients treat study : 1 . Acute myeloid leukemia morphologic CR require treatment disease 6 week 2 . A history AML &lt; 20 % residual blast induction therapy persist &lt; 20 % blast least 8 week without reinduction . 3 . RA RARS isolate 5q proceed transplant without treatment 4 . RAEB1 , RCMD+/RS , MDS NOS stable disease 6 month ( document serial bone marrow examination ) absence therapy growth factor transfusion support . Patients require treatment `` control disease '' must show chemoresponsiveness 5 . CMML RAEB2 must demonstrate chemoresponsiveness . Chemoresponsiveness define blast percentage decrease least 5 percentage point must less 20 % blast treatment time transplant 6 . Hodgkin Indolent NonHodgkin 's lymphoma 7 . Myeloma &lt; 5 % plasma cell marrow 8 . Myeloproliferative disorder 9 . Aplastic Anemia 10 . A hematological oncological disease ( list ) allogeneic HSCT think beneficial , disease chemoresponsive . 11 . Patients without clear manifestation disease status term stage and/or responsiveness discuss PI enrollment analysis document study record . 2 . Patients must relate donor HLA mismatch 2 , 3 , 4 antigen HLAA ; B ; C ; DR loci GVHD direction . ( Patients relate donor HLA identical 1antigen mismatch may treat therapeutic approach , outcomes part statistical aim study ( see Statistical Section ) . The HLA match related category include patient syngeneic donor . 3 . Patients must adequate organ function : 1 . LVEF ( Left ventricular end diastolic function ) &gt; 45 % . LVEF 45 % 54 % must negative stress test increase EF 35 point stress 2 . DLCO ( Diffusing Capacity Lung Carbon Monoxide ) ≥45 % predict corrected hemoglobin , FEV1 ( forced expiratory volume 1 second ≥50 % predict 3 . Adequate liver function define serum bilirubin &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal 4 . Creatinine Clearance ≥ 60 mL/min 4 . HCTCI/Age Score ≤ 5 point 5 . KPS≥ 90 % patient old 70 year , KPS≥ 80 % patient young 70 year 6 . Patients must willing use contraception childbearing potential 1 . Performance status &lt; 90 % patient 70 year old great , &lt; 80 % patient le age 70 year 2 . HCTCI/age Score &gt; 5 point 3 . HIV positive 4 . Active involvement central nervous system malignancy 5 . Inability obtain informed consent patient surrogate 6 . Pregnancy 7 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder 8 . Patients receive alemtuzumab within 6 week transplant admission , recently receive horse rabbit antthymocyte globulin antithymocyte globulin level &gt; 2 ugm/ml 9 . Patients evidence another malignancy , exclusive skin cancer require local treatment , enrol protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>